According to a recent LinkedIn post from Carta Healthcare, a national survey of healthcare leaders by Reaction Data suggests that 67% of professionals view human review of AI output as the primary driver of trust. The post indicates that confidence scores or vendor accuracy claims appear less influential in building clinician confidence.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights the survey’s conclusion that so‑called Hybrid Intelligence, combining AI with human oversight, is perceived as the preferred approach among respondents rather than a fallback. For investors, this emphasis on human-in-the-loop models may signal sustained demand for workflow-integrated AI solutions that prioritize clinician oversight, potentially favoring vendors positioned around hybrid models over fully autonomous systems.
As shared in the post, Carta Healthcare appears to be aligning its messaging with this preference for hybrid approaches, which could differentiate its offerings in an increasingly crowded healthcare AI market. If the broader industry continues to converge on human-supervised AI as a trust standard, companies that design products to fit this model may see fewer adoption barriers with providers and health systems, supporting longer-term revenue opportunities.